Transthyretin amyloidosis market tipped to reach $14.1 billion by 2029

23 July 2020

The transthyretin amyloidosis (ATTR) market is expected to grow from $585 million in 2019 to $14.1 billion in 2029 across the seven major markets, according to GlobalData.

This would put the market on course for a compound annual growth rate (CAGR) of 37.5%, says the company's latest report, titled Transthyretin Amyloidosis: Global Drug Forecast and Market Analysis to 2029.

The report states that growth will be driven by the surge in development of drug therapies of varying mechanisms, and the overall rise in diagnosed patient population due to a much-needed increase in awareness and understanding of the disease among clinicians and the public.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK